Market research
RNA Atrium Therapeutics, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 226M
- P/E ratio
- Not available
- Analyst target
- 25
- Dividend yield
- Not available
- Beta
- 0.93
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04965N1046
- Market cap
- 226M
- P/E ratio
- Not available
- Analyst target
- 25
- Dividend yield
- Not available
- Beta
- 0.93
About
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RNA discussion.
5 years, 4 months ago
Avidity Biosciences, Inc is currently in a long term downtrend where the price is trading 12.5% below its 200 day moving average.
From a valuation standpoint, the stock is 94.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 71.5.
Avidity Biosciences, Inc's total revenue rose by 48.2% to $2M since the same quarter in the previous year.
Its net income has dropped by 56.5% to $-16M since the same quarter in the previous year.
Finally, its free cash flow fell by 160.5% to $-13M since the same quarter in the previous year.
Based on the above factors, Avidity Biosciences, Inc gets an overall score of 2/5.